Abstract Motorneuron degenerative diseases, such as amyotrophic lateral sclerosis (ALS), are characterized by the progressive and rapid loss of motor neurons in the brain and spinal cord, leading to paralysis and death. GDNF (glial cell line derived neurotrophic factor) has been previously shown to be capable of protecting motorneurons in ALS animal models although its delivery to the spinal cord after systemic administration is blocked by the blood brain barrier. Thus, it is necessary to develop new neurotrophic approaches to protect these motor neurons from death. Bone marrow-derived stem cells have been shown to be capable of improving a large variety of neurodegenerative disorders through neurotrophic mediated mechanisms. Here we analyzed the effect of transplanting whole bone marrow or cultured mesenchymal stem cells into the spinal cord of a motor neuron degenerative mouse model. Motor functions were analyzed using various behavior tests for several weeks after transplantation. We observed that bone marrow, and to a lesser degree mesenchymal stem cell, treated mice improved significantly in the motor tests performed, coinciding with a higher GDNF immunoreactivity in the grafted spinal cord. In several cases, the treated spinal cords were extracted, the engrafted bone marrow cells isolated and cultured, and finally re-transplanted into the spleen of immunodeficient mice. Re-grafted cells were detected in the host spleen, bloodstream and bone marrow, demonstrating a phenotypic stability. Thus, bone marrow cells do not suffer significant phenotypic modifications and is an efficient procedure to ameliorate motor-neuron degeneration, making it a possible therapeutic approach.
Introduction
There are many motor neuron degenerative diseases, being amyotrophic lateral sclerosis (ALS) one of the most well known. This disorder, also known as Lou Gehrig's disease, mainly affects the spinal cord, brainstem and motor cortex [1] . The loss of motor neurons and their muscle synapses eventually leads to spasticity, hyperreflexia (when upper motor neurons are exclusively affected), generalized weakness, muscle atrophy, dysphagia, and premature death due to respiratory failure [2, 3] . The cause of this degeneration is unknown in the majority of cases, and the clinical course is highly variable, suggesting that multiple factors are involved in the development of the disease, although several hypotheses have been proposed, including mitochondrial dysfunction, protein aggregate formation, excitotoxicity, axonal transport malfunction, mutant-derived oxidative damage, lack of growth factors, and inflammation [4] .
As ALS, other related disorders such as spinal muscular atrophy (SMA) and progressive muscular atrophy (PMA) present motor neuron degeneration [5, 6] . Many authors have studied the use of stem cells to treat SMA [7] or ALS [8] , by transplanting bone marrow-derived stem cells in transgenic animal models, in order to try to ameliorate the symptoms or delay the onset of the disease, with varied results [8] [9] [10] .
Recent data has shown that transplanting bone marrow cells from healthy animals increases motor neuron survival [11] . In our lab, we have previously shown that hematopoietic stem cells, when transplanted into the lumbar regions of the spinal cord, are capable of protecting motor neurons from entering apoptosis due to a trophic effect by the expression of GDNF [12] . This neurotrophic factor, known to improve neuronal survival, is not capable of passing through the blood-brain barrier [13] , thus its systemic administration is severely limited. Other methods for GDNF incorporation, such as intraventricular administration, could have significant collateral effects, affecting different aspects of the blood-brain barrier's function [14] .
Several authors have shown that bone marrow cells can not only ameliorate the symptoms but also support striated muscle regeneration [11] as well as improve electromyographic signalling [12] . Also, mesenchymal stem cells are capable of reducing the reactive gliosis and microglia activation that is typical in rodent models of ALS, resulting in improved motor skills as detected through various behavior tests [15] . Unfortunately, the methods by which these cell transplants avoid motor neuron death are not well understood. Thus, the objectives in this work are to analyze if whole bone marrow transplants or pure mesenchymal stem cells are capable of improving the motor functions of an ALS mouse model, and characterize the process by which these cells induce this improvement.
Materials and Methods

Animals
All animal experiments have been performed in compliance with the Spanish and European Union laws on animal care in experimentation (Council Directive 86/609/EEC), and have been analyzed and approved by the Animal Experimentation Committee of our university. Mice with the muscle deficient/osteocondrodystrophy mutation (mdf/ ocd) were obtained from the Pasteur Institute (Paris, France), as a gift from J.L. Guenet. These mice suffer from a currently unidentified autosomal-recessive spontaneous mutation, located on chromosome 19. Homozygous mdf mutant mice begin to present motor dysfunctions in their hindlimbs at 3 weeks of age, which progresses to hindlimb paralysis and forelimb weakness [16] . Our mdf/ocd model was first described by Poirier [17] and has recently been shown to be affected by a loss of function in Scyl1 [18] , thus the mouse model presents, in addition to motor neuron degeneration, cerebellar atrophy, purkinje cell loss and optic nerve atrophy. In our animal facilities, we have seen that they present a lifespan similar to wild-type mice. For the experiments, a total of 14 animals were used for post-graft spinal cord cultures (10 symptomatic and 4 non-symptomatic), 20 mice for ELISA measurements and 21 mice for immunohistochemistry and behavior tests. As a control for ELISA measurements we used 6 C57BL/6 mice, the original background for the mdf mutation [16] .
The green fluorescent protein (GFP) mutant mice (C57Bl/6-Tg(ACTB-EGFP)1Osb/J) used were bred in our animal facilities. These mice ubiquitously express the GFP protein under the control of the beta-actin promoter [19] , which facilitates their detection when transplanted into a host that does not present the GFP protein. Immunodeficient mice (Athymic Nude-Foxn1 nu ) were purchased from Harlan Laboratories, Switzerland. GDNF/LacZ knockout mice were bred in our animal facilities. Homozygous mice die at birth, while heterozygotes are viable and used to maintain the colony [20] .
Isolation of Bone Marrow Cells
Femurs were dissected from 6-to 8-week old GFP + mice, sacrificed by cervical dislocation. Bone marrow was extracted, and single-cell suspensions were obtained by mechanical dissociation. The cells were then counted and resuspended in standard basal medium (D-MEM, Invitrogen) to obtain a concentration of 1×10 6 cells in 5 μl for the transplantation of whole bone marrow cells (BMC).
Isolation and Culture of Bone Marrow-Derived Mesenchymal Stem Cells
Unless stated otherwise, all the materials and substances were purchased from Sigma-Aldrich. Bone marrow was extracted as previously commented, obtaining a cell suspension. The cells were washed and centrifuged, and the pellet was then resuspended in D-MEM (Invitrogen) supplemented with 15% FBS (Biochrom AG, Berlin), 100 U/ml penicillin/streptomycin, 1 mM sodium pyru-vate, and 1% non-essential amino acids. These cells were placed in culture flasks and the plastic-adherent population was isolated and allowed to proliferate for 3-4 weeks, changing the media twice a week. Approximately every 7 days, the cells were tripsinized with tripsine/EDTA 0.25% and replated. After 3-4 weeks, all the cells in culture expressed CD90 and CD44 and were negative for CD34 and CD45, confirming that the cell population was mainly composed of mesenchymal stem cells (MSC, data not shown) [21] .
Isolation of Bone Marrow and Spleen Cells from GDNF Knockout Mice
Pregnant heterozygous GDNF knockout mice were sacrificed 20 dpc and fetuses separated. The fetuses that did not present kidneys, indicating that they are homozygous mutants, were selected [20] . Femur bone and spleen were extracted, minced, centrifuged and resuspended in DMEM for transplantation. Control fetuses were isolated in parallel to demonstrate that newborn GFP bone marrow cells produce the same effects as adult bone marrow.
Behavior Assays A total of 3 tests were performed on the mdf mutant mice: footprint analysis to study stride length, accelerating rota-rod analysis, and maximum speed in a treadmill. These tests were performed on a weekly basis for 3 weeks before the transplantation process. After the transplant, the mice were allowed to recover for 1 week, and then submitted again to the weekly behavior tests during at least another 3 weeks. Mice where only standard culture medium was injected were used as controls, which were submitted to the same tests as those performed by the experimental mice.
Footprint (FP)
The hindlimb paws of the mice were painted with non-toxic, washable paints purchased from an ordinary paint shop. Then, they were placed in an opaque methacrylate tube with a blackcolored cardboard box attached to one of its ends. The tube and box were placed over a 60 cm long by 10 cm wide strip of paper, where the mouse was expected to walk towards the darkness of the cardboard box, leaving its footprints on the paper. In this manner, the stride length could be measured, as it has been previously shown that mice with affected motor functions have a decreased stride length [22] .
Rota-Rod (RR)
The rota-rod test was performed on an 8500 Rota-rod (Leica Scientific Instruments, Barcelona, Spain). The lane is 500 mm wide, and the rod has a diameter of 30 mm. Before analysis, the mice were trained on the rod for 4 days until they presented an adequate walking pace. Afterwards, the mice were tested weekly, placing each mouse 8 times on the accelerating rota-rod cylinder, which uniformly increased speed from 4 to 40 rpm over a 5 min time span, until the mouse fell. Both the time of fall and speed reached were recorded and averaged per session [12, 23] .
Treadmill (TM)
An LE 8700 treadmill model was used (Leica Scientific Instrument). The lane is 41 mm long and 10 mm wide. The runway, when in movement, pushes the animal to the shock grid, set at 0.4 mA. In this manner, it was possible to measure the maximum possible speed each mouse may attain. The treadmill accelerated at a constant rate until the mouse could not maintain the speed, and the maximum speed reached was noted. Before analysis the mice were trained for 2 days with the apparatus. Then, each mouse was placed 8 times in the treadmill per session and the average maximum speed attained was calculated. Other authors have analyzed the maximum speed attained in neurodegenerative animal models, however this is the first report to use the treadmill for this end [24] .
Cell Transplantation
The mice were injected intraperitoneally with 0.1 mg of buprenorphine (Buprex, Schering-Plough, Madrid, Spain) per kilogram of mouse previous to the surgical intervention. Then, they were anesthetized with isofluorane gas (Esteve Veterinary, Milan, Italy) and placed in a stereotaxic apparatus (Stoelting, Wheat Lane Wood Dale, Indiana). A laminectomy was performed at the L5-S1 level, and the cells were injected under a surgical microscope with a Hamilton syringe (Hamilton, Reno, Nevada) into the anterior horn of the spinal cord through the posterior funiculus at 0.2 mm of the dorsal sulcus. Depending on the case, either one million bone marrow-derived cells (BMC) (either from GFP or GDNF-KO mice), 500,000 mesenchymal stem cells (MSC), or fresh culture medium were injected, all in a maximum volume of 5 μl.
After the injection, the incision was sutured and the mice were monitored until they recovered from the anaesthesia and during the following days in order to ensure that the operation did not cause any additional motor damage, such as paralysis or tremors in the hindlimbs.
Spinal Cord Culture
In order to analyze the viability and in vitro phenotype of the transplanted cells, BMC [6] and MSC [4] -treated mice were sacrificed and their spinal cords removed for cell culture. Specifically, sections L4 to S2 were extracted and dissociated mechanically and enzymatically with 3 mg/ml collagenase I during 15 min at 37°C. The resulting cell suspension was washed, centrifuged and resuspended in MEM medium supplemented with 10% Calf serum, 2 mM glutamine, 100 U/ml penicillin/streptomycin, 1 mM sodium pyruvate and 1% non-essential amino acids.
Transplantation of Previously Grafted Bone Marrow Cells into Nude Mice
For this experiment, the spinal cord cultures isolated from BMC-treated mice were used. The cells were unattached with tripsine/EDTA 0.25%, washed and resuspended in 50 μl MEM, which was injected into the spleen of immunodeficient nude mice (Athymic Nude-Foxn1 nu , Harlan Laboratories, Switzerland). The surgical procedure was similar to the spinal cord transplants, only in this case the mouse was placed over its back to reach the spleen. After 15 days, the nude mice were sacrificed, blood extracted and its bone marrow isolated and cultured as previously commented. The spleen, liver, lung, and brain were fixed in 4% paraformaldehyde for 24 h before their histological analysis.
Tissue Preparation and Immunohistochemistry
Three to four weeks after the injection/grafting, the mice were anesthetized with isofluorane and fixed by intracardiac perfusion with 4% paraformaldehyde (PFA) in phosphate buffer (pH 7.4). The spinal cord was carefully excised and kept in 4% PFA overnight. After fixation, the spinal cords were cryoprotected by increasing concentrations of sucrose and finally embedded in Tissue-Tek (Electron Microscopy Science, Hatfield, PA) and frozen. Transverse sections of 20 μm were obtained with a cryostat and mounted on slides. The sections were incubated for 60 min at room temperature in 0.1% lysine in PBS to block non-specific binding. The following primary antibodies were used: anti-GFP (rabbit or mouse, 1:200, Molecular Probes, Eugene, OR), anti-GDNF (rabbit, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD34 (rat, 1:250, eBioscience, San Diego, CA), anti-CD44 (rat, 1:250, BD Biosciences Pharmingen, San Diego CA), anti-CD45 (rat, 1:250, BD Biosciences Pharmingen), anti-CD90 (rat, 1:250, BD Biosciences Pharmingen), Tuj-1 (mouse, 1:1000, Covance, Berkeley, CA), anti-active caspase-3 (rabbit, 1:500, BD Pharmingen), and beta-galactosidase antibody (chicken, 1:400, Abcam). The sections were incubated overnight at room temperature with the primary antibody. Afterwards, in all cases except for GFP staining, biotinylated secondary antibodies (1:200, Vector Laboratories, Burmingham, California) or rabbit polyclonal secondary antibody to chicken IgY (1:200, Abcam) were used, followed by an incubation with streptavidin conjugated either with Cy3 (1:500, GE Healthcare, Buckinghamshire, UK) or Alexa Fluor 488 in the case of GFP (mouse or rabbit, 1:500, Molecular Probes). Histological samples were observed in a fluorescence microscope (Leica DMR, Leica Microsystems) and micrographs taken with a confocal microscope (Leica DMR).
Enzyme-Linked Immunosorbent Assay (ELISA)
A group of 26 animals was used to study the possible neuroprotective effects of glial cell line derived neurotrophic factor (GDNF) levels in the grafted spinal cord area. Seven days after surgery, the mice were anesthetized with an overdose of sodium pentobarbital (100 mg/kg) and decapitated. Different groups of animals were used: wild-type mice C57 (n=6), nontreated mdf/ocd clinically affected animals (n=6), BMC transplanted mdf/ocd affected animals (n=7) and MSC transplanted mdf/ocd affected animals (n=7). The lumbosacral (L4-S1 segments) enlargement of the spinal cords was removed within 3-5 min after decapitation. Tissue was stored at −80°C. All samples were used within 15 days after freezing. The tissue levels of GDNF were measured with an ELISA kit (GDNF Emax ImmunoAssay System; Promega, Madison, WI), according to the protocol of the supplier.
Statistical Analysis
Statistical analysis was performed using SigmaPlot 10.0 software. Both paired t-student tests (for behavior assay) and t-student (for protein quantification) were used.
Results
Whole Bone Marrow Transplants Significantly Improve the Motor Functions of the Mice
A total of 21 symptomatic mdf/ocd mice were used for this experiment, placed in three groups, depending on the cell source transplanted: 9 transplanted with whole bone marrow (BMC), 6 with mesenchymal stem cells (MSC), and 6 controls where only culture medium was injected (SHAM). The mice were submitted on a weekly basis to three behavior tests before and after the transplantation: treadmill, rota-rod and footprint (Fig. 1) . The degeneration in mutant mice were found to progress in two different manners: either presenting acute, fast degeneration detected by the decreasing scores obtained in the various tests throughout the pre-grafting period (footprint n=7, rotarod n =6, treadmill n =5) (Fig. 1a represents the rotarod results), or a slow degeneration (footprint n=10, rotarod n=7, treadmill n=12), obtaining low yet somewhat stable scores (Fig. 1b represents the rotarod results) .
The results of the behavior tests varied significantly depending on the experimental treatment (Fig. 1c) . In the case of the BMC mice, 2 out of 9 improved in one of the three tests, while 3 mice improved in two tests. As for the MSCtreated mice, only 2 of 6 mice improved significantly in one of the tests, with no mice improving in more than one test. None of the controls improved in any of the behavior tests.
By studying each of the behavior tests independently, we detected that none of the MSC mice improved in the footprint test (Fig. 1c) . On the other hand, one third of the BMC mice (3 of 9) improved in this test.
As for the rotarod test, symptomatic mdf mice gradually attained lower values on the accelerating rotarod, corresponding to the degeneration of the hindlimb motor neurons as well as the cerebellar degeneration due to the Scyl1 mutation. Since Schmidt et al. [18] reported that at 274 days there was still 42% of Purkinje cell remaining in the mdf mice, and no functional data was presented in their work, we think that our early functional phenotype (analyzed at 45-90 postnatal days) was mainly due to motorneuron degeneration. In the transplanted mice the significant improvements were evaluated with the paired t-Student test. In this case, 22% (2 of 9) of the BMC presented a significant improvement in the rotarod, compared to 16% of the MSC (1 of 6).
In the treadmill tests, the mice gradually improved their motor performance, obtaining increasingly higher values. As in the other cases, the non-transplanted symptomatic mice gradually presented lower values, probably due to their neuronal degeneration. A third (3 of 9) of the BMC mice and 16% (1 of 6) of the MSC improved in this test.
Thus, as it can be seen, the two cellular treatments have different results on the mice. Specifically, bone marrow transplantation significantly improved the motor skills in 55% of the treated mice (33% in more than one test), compared to 33% of the mesenchymal stem cell-treated mice (with none improving in more than one test). No MSC-treated mice improved in the footprint test. The cells were injected into the anterior horn of the spinal cord, as depicted in Fig. 2a . After the experimental phase, which lasted for 3 weeks, the mice were perfused and spinal cords analyzed by immunohistochemistry. In BMC grafted mice, round-shaped GFP+ cells were detected forming a cluster at the injection site, with many dispersed cells surrounding it. Also, a number of cells could be detected as far as 0.5 cm away from the central region of the grafted area in both directions: rostrally and caudally (Fig. 2b) . The grafted cells were either spherical-shaped or presented short prolongations (Fig. 2c-e) . The majority (90%) of the cells expressed CD45 and CD34 (hematopoietic markers), and a few (10% approximately) were CD44 or CD90 positive (mesenchymal markers) (Fig. 2f-i, respectively) . Eighty percent of the BMC transplanted mice presented GFP + cells; however, only 30% of the MSC grafts presented an equivalent distribution of live GFP + cells as those found in the BMC grafts, in the rest of cases the cells appeared largely disseminated and in very low numbers. In this case, the cells were mainly small, round-shaped, and found either in clusters or as individual cells surrounding the cluster (Fig. 2j) . Also, in the mice with the most numerous GFP + cells, these were found many times in blood vessels (Fig. 2k) , possibly contributing and promoting angiogenesis, as it has been previously described [25] . These cells maintain the expression of the surface marker CD90 (Fig. 2l) . In both cases, the regular morphology of the cell body, and the absence of cells with more than one nucleus indicated that there was no sign of transdifferentiation or cell fusion.
Increased Levels of GDNF in the BMC Mice GDNF expression was analyzed in the treated (BMC and MSC) and non-treated mice (Fig. 3) . GDNF immunoreactivity was detected in the area where BMC cells were transplanted and its expression decreased when we observed areas farther away from the transplant (Fig. 3a) . As for the MSC-treated mice as well as in the control group, there was no significant expression of this neurotrophic factor (Fig. 3b-c, respectively) . In areas where the grafted cells were detected near the motorneurons, these neurons were GDNF positive, which was not detected in other motor neurons that were far from the grafted cells ( Fig. 3d and e, respectively; p=0.028) .
Quantification of GDNF expression in the grafted area of the spinal cord was performed using the ELISA test (Fig. 3f) . In the BMC grafted group, there was a significantly higher concentration of GDNF compared to the non-treated control group (39.5.1±12.8 pg/mg and 27.8±9.7 pg/mg, respectively). In the MSC grafted group, GDNF concentration was similar (40.7±20.9 pg/mg) to BMC grafted mice (39.5.1±12.8 pg/mg), however due to its high variability, it was not significantly higher than the NT group (p=0.094).
Bone Marrow-Derived Cells Maintain Proliferative Capabilities in the Post-Graft Culture, Whereas
Mesenchymal Stem Cells Enter Apoptosis
To analyze the viability of the grafted cells and their phenotypic characteristics, active caspase-3 was studied in the spinal cord (Fig. 4) . In the BMC grafted group, 35% of the cells were active caspase-3 positive (Fig. 4a) . However, in the MSC group, 80% of the cells expressed active caspase-3 (Fig. 4b) , indicating that the mesenchymal stem cells do not survive well in the spinal cord, and thus enter apoptosis.
Three weeks after the transplantation, 6 BMC and 4 MSC mice were sacrificed, and their spinal cord removed for cell culture. In the MSC graft cultures, no GFP+ cells were detected (data not shown). In BMC graft cultures, donor cells were detected in all the spinal cord cultures. Several GFP positive cells were found as early as 1 day after culture, many of which were in contact with host cells (Fig. 5a ). The majority of the host cells were Tuj1 positive, indicating a neuronal phenotype. BMC cells were also transplanted into non-symptomatic mice, maintained for 3 weeks and spinal cords removed for cell culture (n= 4). In this case, there was 80% more GFP+ cells in culture compared to the cultures of BMC symptomatic mice (n =4, Fig. 5b and c, respectively) . We believe this was due to the neurodegenerative environment of the spinal cord in the mutant mice, which probably created a different niche that modified in some way the culture properties of grafted cells.
Nevertheless, the majority of the surviving cells in culture were CD45 positive, indicating that they still maintained their bone marrow phenotype, and were of hematopoietic origin (Fig. 5d-f ).
Post-graft Cultured Bone Marrow-Derived Cells, When Transplanted into the Spleen of Nude Mice, Enter the Bloodstream and Migrate to the host's Bone Marrow
The bone marrow-derived cells that were cultured in the postgraft protocol were re-transplanted into the spleen of nude mice. After 3 weeks, the mice were sacrificed and several organs were analyzed by immunohistochemistry, including the spleen, lungs, liver, brain as well as the bone marrow and peripheral blood. GFP positive cells were detected in the spleen (Fig. 6a) , as well as in the bone marrow of the nude mice (Fig. 6b-c) . These cells were initially round-shaped, but soon adopted an elongated morphology. Thus, the cells, once re-transplanted into the spleen, travelled through the bloodstream and populated the host's bone marrow, its natural niche.
Donor GDNF Expression is Necessary to Improve Motor Behavior in Mdf Mice
To confirm that donor GDNF expression is necessary for motor-neuron survival, we transplanted bone marrow and spleen cells of GDNF knockout (GDNF KO) mice in the spinal cord of mdf mice (n= 4). Since this mouse model dies at p1 [20] , it was necessary to isolate cells from the bone marrow and spleen at p0. As controls we used newborn beta-actin GFP mice (n=6). As a result, no significant improvements were detected in the behavior tests of GDNF KO bone marrow-treated mice, while the mice treated with GFP-bone marrow presented similar results as with adult bone marrow (Fig. 7a) . The grafted cells of both GDNF KO and GFP cells were detected in the anterior horn of the lumbar region (Fig. 7b and c, respectively) . In several cases, the animals were sacrificed and analyzed for GDNF quantification (GDNF KO n=3, GFP n=4) by ELISA. GDNF KO bone marrow cells did not increase the GDNF content of the spinal cords, as opposed to the GFP cells, corroborating the importance of GDNF expression of the donor cells (Fig. 7d) .
Discussion
In this work we have shown that transplantation of whole bone marrow (BMC), and to a lesser degree mesenchymal stem cells (MSC), is capable of ameliorating the symptoms of a motor neuron degenerative mouse model. Over half of the BMC grafted mice improved in at least one of the behavior tests, and 33% improved in two. Interestingly, in the case of mesenchymal stem cell grafts, one third significantly improved in one behavior test, with none improving in more than one. In our experiments, BMC presented better results than MSC when comparing the motor function of the treated mice. Also, BMC had a higher survival rate in the spinal cord, where 80% of the BMC grafted mice presented donor cells at the moment of sacrifice compared to 30% of MSC grafted mice, which As opposed to our previous work [12] , where hematopoietic stem cells were isolated and transplanted, here we grafted whole bone marrow as well as mesenchymal stem cells for several reasons. First of all, bone marrow cells are relatively easy to obtain, requires minimum manipulation, and can be extracted and rapidly re-implanted into the region of interest. As for the mesenchymal stem cells, their neuroprotective effects are well known and can be easily expanded in culture. Bone marrow contains hematopoietic stem cells, endothelial cell progenitors, mesenchymal stem cells, as well as other cell types that may differentiate into immature or mature nonhematopoietic cells of multiple tissues [26] , which possibly produce or induce the observed trophic effect. Interestingly this effect was not observed in the transplants using mesenchymal stem cells. In the BMC- The majority of the transplanted cells maintained their spherical morphology as well as their original bone marrow markers, although we could easily find cells with several prolongations that may possibly be contacting adjacent cells. These cell contacts could underlay the production of neurotrophic factors such as GDNF by these cells. Our experiments with GDNF-KO mice show that the grafted cells produce this neurotrophic factor, thereby increasing GDNF expression in the spinal cord, resulting in improved motor coordination. Also, our experiments with newborn GFP bone marrow obtained similar results to those seen with adult bone marrow, indicating that the results obtained with GDNF-KO bone marrow is due to the lack of this trophic factor.
In the BMC-treated mice, the majority of the grafted cells were clustered in the injection site; however cells could be detected as far as 0.5 mm away from the transplanted area. Interestingly, many cells were also detected surrounding blood vessels. In BMC transplants, the majority of the cells expressed CD45 or CD34, indicating a hematopoietic lineage, although mesenchymal markers such as CD44 and CD90 were also detected. In both cases (BMC and MSC), the cells did not express any of the neuronal markers analyzed, thus there was no indication of cell fusion nor transdifferentiation, and no tumor formations were observed, as other authors have shown [27] [28] [29] [30] . Mesenchymal stem cells stop proliferating due to contact inhibition [31] , which is an important property to consider in cell therapy in order to avoid tumor formation. This phenotypic stability is of great importance, since any external modification of the grafted cells, even towards normal characterization, would increase the risk of collateral effects after cellular therapy.
We have used the mdf/ocd mouse model for this experiment because we believe it to be an interesting rodent model for motor neuron degeneration. Many authors use SOD1 mutant mice and rats, which possess traits found in only 2-3% of the human ALS patients [32, 33] . The striking pathological and clinical similarity between familial and sporadic disease has sparked enthusiasm that the animal models based on mutant SOD1 might provide insight into mechanisms of both sporadic and familial disease. However, to date, there is no direct evidence validating this assumption [2] . Mdf is an autosomal-recessive mutation located in mouse chromosome 19 [16, 17] . These mice present successive motor neuron death that result in a posterior waddling at 4-8 weeks of age. This waddling is progressive until reaching hindlimb paralysis and forelimb weakness, with the mouse ultimately dying generally due to respiratory failure. In the skeletal muscles it is possible to observe neurogenic atrophy, as well as axonal degeneration in the peripheral nerves. In the spinal cord, the neurons degenerate and there is an astrogliosis restricted to the ventral horn of the spinal cord. These traits make the mdf/ ocd mouse a highly appropriate model for the study of motor neuron degeneration, presenting a longer lifespan compared to SOD1 mutant mice. Recently, this mouse model has been shown to be affected by a loss of function of the Scyl1 gene [18] , and includes cerebellar degeneration. The Scyl1 gene mutation in humans produces Scyl1-encoded protein that interacts with the survival motor neuron and Purkinje cells, a possible cause for spinal muscular atrophy and spinocerbellar ataxia.
There are several methods by which bone marrow cells are capable of improving the symptoms of diseased models [12, 34] . Besides cell fusion and transdifferentiation, bone marrow cells possess immunomodulatory properties [15] , and can release trophic factors. In the latter case, bone marrow cells produce and secrete a large variety of trophic factors, such as VEGF, NGF, BDNF, and GDNF, among others [21, [35] [36] [37] [38] [39] [40] [41] . Several of these trophic factors have been shown to ameliorate the degeneration of motor neurons in various animal models [42] [43] [44] [45] , which has resulted in the development of various clinical trials for ALS [10, 45] . Of these factors, GDNF has been proven to protect the degenerating motor neurons [46] . This was achieved by transplanting human neural progenitors, genetically modified to secrete GDNF, in the spinal cord of an ALS rat model. As a result, the dying motor neurons were rescued, but their axonal projections to the muscle were lost. Our results show that bone marrow stem cells are capable of not only protecting the motor neurons but also their projections, increasing significantly their motor functions. Also, we have shown that the cells are capable of inducing GDNF expression, thus whole bone marrow can be used as a vehicle to increase GDNF expression in the damaged spinal cords, avoiding motor degeneration. This increased GDNF is restricted to the area the cells are transplanted, thus it is possible that the factors released by the grafted cells to the adjacent motor neurons increase their probabilities of survival and thus avoid the loss of motor functions, as opposed to a possible recovery of lost neurons. In addition, retrograde trophic effects may act through the activation of GDNF axonal receptors in cortical motor neurons, thus also activating neurotrophic mechanisms in the motor cortex.
In conclusion, whole bone marrow transplantation is a relatively simple method to consider as a potential treatment of motor neuron degenerative diseases, capable of ameliorating its symptoms by reducing motor neuron death, inducing GDNF production, ultimately resulting in an improvement of the host's motor functions.
